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Objectives:  The  purpose  of this  study  was  to  analyze  the  outcome  of  patients  suffering  from  head  and
neck  sarcomas  and  to  identify  indicators  of outcome.
Material  and  methods:  The  medical  records  of  43  patients  treated  between  2000  and  2010 were  analyzed.
All  patients  were  suffering  from  primary  head  and  neck  sarcoma.  The  ﬁnal  study  sample  included  29
patients.
Results:  Mean  survival  was  56  months.  Overall  2-  and  5-year  survivorship  was  69%  and  31%  respectively.
Parameters  positively  inﬂuencing  survival  were:  male  gender;  non-smoker;  alcohol  consumption;  age
< 18  years;  tumor  size  <  5 cm;  location  (nasal  pyramid,  jaw  and  maxillary  sinus).  Rhabdomyosarcoma
and  synovial  sarcoma  were  the  histological  forms  positively  inﬂuencing  prognosis.  Age  was  the only
parameter  signiﬁcantly  inﬂuencing  survival  (P  <  0.05).
Conclusions:  The  present  overall  5-year  survivorship  was  similar  to the  lower  limit  of the  available  litera-
ture data.  Age  was  the  only proven  indicator  of outcome.  In  order  to  have  more  reliable  data  it  is  essential
to  set  up  broader  databases.. Introduction
Sarcoma of the head and neck is very rare, representing only 1%
f all primary tumors arising within the head and neck region [1],
nd accounting for 4–10% of all sarcomas [2].
Sarcomas are divided into two types: soft tissue sarcomas and
one/cartilage sarcomas [3]. Most (∼80%) are of soft tissue origin,
ith only 20% of bony or cartilaginous origin [1].
They originate from mesenchymal cells and are a diverse group
hat arises from many different tissues, including bone, cartilage,
uscle, fat, blood vessels and nerves [2].
Sarcomas of the head and neck are malignant tumors with a
ide spectrum of histological subtypes and sites of origin, but are
rouped together because of similarities in prognostic factors, clin-
cal presentation, derivation from the embryonic mesoderm and
verall outcome [4].
Although more than 50 histological subtypes have been identi-ed, the current staging criteria used to determine treatment are
niversal for almost all subtypes and depend on the histological
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grade, tumor size and depth, as well as the presence of remote or
regional metastases [4].
Management of these neoplasms presents a great challenge [5].
The general concepts of sarcoma management are not univer-
sally applied in head and neck. The delicate anatomy of the head
and neck limits the ability to obtain wide surgical margins. This may
be the reason why  there is a higher local recurrence rate and worse
disease-speciﬁc survival in head and neck sarcomas compared to
other sites [5].
The optimal treatment is complete resection [6].
Due to the rarity of head and neck sarcomas in adults and the
small number of treatment centers, there is not enough clinical
evidence-based data in the literature to provide sufﬁcient patient
numbers to identify prognostic factors or associated inﬂuences on
overall survival [4].
As a result, information about sarcomas is scattered throughout
the literature.
There is an urgent need for reliable data [2].
The aim of this study is to analyze the clinical ﬁndings, manage-
ment and survival of patients suffering from head and neck sarcoma
and to ﬁnd indicators of outcome.2. Materials and methods
A retrospective study was conducted from 2000 to 2010, based
on analysis of 43 patients’ medical records.
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Table  1
Case details.
Case Age Gender Smoking Alcohol Size (cm) Location Histology Surgery CT RT Survival (months) Recurrence
1 5 M − − 2 Maxillary sinus Rhabdomyosarcoma + + + 322 +
2  41 F − − 2 Mandible Synovial sarcoma + − + 144 +
3  65 M + + 2 Gingival mucosa Malignant ﬁbrous histiocytoma + + + 77 −
4  67 F − − 7 Maxillary sinus Osteosarcoma + − + 12 +
5  90 M − − 1 Buccal mucosa Kaposi’s sarcoma + − − 34 −
6  25 M − − 4 Mandible Osteosarcoma + − − 118 −
7  71 F − − 5 Maxillary sinus Osteosarcoma − − − 12 −
8  44 M + + 3 Gingival mucosa Leiomyosarcoma − − − 1 −
9  6 M − − 2 Nasal pyramid Rhabdomyosarcoma + + + 120 +
10  79 M − − 7 Larynx Osteosarcoma + − − 4 −
11  58 F − − 4 Maxillary sinus Osteosarcoma + + + 35 +
12  41 M + + 3 Nasal pyramid Chondrosarcoma + − + 99 +
13  48 M − + 2 Maxillary sinus Angiosarcoma + + + 136 +
14  50 M − − 2 Tongue Leiomyosarcoma + + + 11 +
15  16 F − − 5 Tongue Osteosarcoma + + + 82 −
16  70 M + − 3 Larynx Chondrosarcoma + − − 47 −
17  5 M − − 6 Mandible Rhabdomyosarcoma + + + 22 +
18  54 M − − 4 Larynx Leiomyosarcoma + − − 53 −
19  21 M − − 3 Maxillary sinus Rhabdomyosarcoma + + + 25 +
20  44 F − − 3 Gingival mucosa Angiosarcoma + + + 48 +
21  9 M − − 4 Nasopharynx Osteosarcoma + − − 43 −
22  30 M − − 1 Larynx Rhabdomyosarcoma + + + 37 −
23  71 F − − 4 Maxillary sinus MPNST + − − 29 +
24  81 F − − 5 Maxillary sinus Osteosarcoma + − + 26 −
25  26 M − − 5 Mandible Osteosarcoma + + + 22 +
26  24 M − − 4 Maxillary sinus Angiosarcoma + + + 32 +
27  74 M − − 11 Maxillary sinus MPNST + − − 7 −
28  44 M − − 3 Maxillary sinus Osteosarcoma + + + 32 +
PNST + − − 6 −
M apy; F: female gender; RT: radiotherapy; +: presence; −: absence.
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Table 3
Mean survival (MS) details. Mean survival per histological subtype.
Histology n MS
Osteosarcoma 10 39.3
Non-osteosarcoma 19 65.8
Rhabdomyosarcome 5 105
Angiosarcoma 3 72
Leiomyosarcoma 3 21.7
MPNST 3 3 14
Chondrosarcoma 2 73
Kaposi’s sarcoma 1 34
six cases (21%).
Most tumors were smaller than 5 cm (20 cases, 69%).29  72 F − − 6 Maxillary sinus M
PNST: malignant peripheral nerve sheath tumor; M:  male gender; CT: chemother
Histologically proven, sarcoma of the head and neck was  the
nly inclusion criterion.
Insufﬁcient information about any of the analyzed parameters
as the only exclusion criterion.
We had access to 29 cases with complete information (Table 1).
Epidemiological parameters and patient survival were recorded.
Age, alcohol consumption, smoking, gender, tumor location,
reatment (radiotherapy, chemotherapy or surgery), metastases,
umor recurrence and histological subtypes were theparameters
nalyzed.
All statistical analyses were carried out using the IBM-
PSS version 18.0 software package (International Business
achines – Statistical Package for the Social Sciences – Armonk,
ew York, USA). Survival curves were calculated using the
aplan–Meier method.
The area under the curve was calculated with 95% conﬁdence
nterval.
. Results
The study sample included 20 males and nine females, aged
etween 5 and 90 years (Tables 2–6).
Mean age was  45.9 ± 25 years.
The most frequent symptoms at presentation were: neck mass62%), epistaxis (14%) and dysphonia (14%).
Osteosarcoma was the most common tumor, arising in 34% of
atients (10 cases).
able 2
ean survival details. Overall survival (OS).
Overall survival n OS (%)
24 M 1 20 69
60  M 2 9 31
:  month.Synovial sarcoma 1 144
Malignant ﬁbrous histiocytoma 1 77
The remaining histologically conﬁrmed sarcomas were rhab-
domyosarcoma (5 cases, 17%), angiosarcoma, leiomyosarcoma,
malignant peripheral nerve sheath tumor (3 cases each, 10%), chon-
drosarcoma (2 cases, 7%), and Kaposi’s sarcoma, synovial sarcoma
and malignant ﬁbrous histiocytoma (1 case each, 3%).
The most common locations were the maxillary sinus and upper
aerodigestive tract, with 11 patients each (39%), and the face withTable 4
Mean survival details (MS). Mean survival per location.
Location n MS
Maxillary sinus 12 56.2
Larynx 4 32.5
Mandible 4 76.5
Gengival mucosa 3 42
Nasal pyramid 2 110
Tongue 2 46.5
Nasopharynx 1 43
Buccal mucosa 1 34
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Table  5
Mean survival details (MS). Mean survival per treatment subtype.
Treatment n MS
Surgery
With 24 55.7
Without 5 33.3
Surgical margins
Impossible to test 11 59.3
Close 4 50
Negative 9 55.3
Positive 5 19.8
Radiotherapy
With 18 55.6
Without 11 47.6
Chemotherapy
With 14 66.7
Without 15 39.7
Chemoradiotherapy
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Fig. 1. Kaplan–Meier 5-year overall survival curve (60 months).With 14 71.5
Without 15 42.3
Surgery was the most frequent treatment (24 cases, 83%), fol-
owed by radiotherapy (18 patients, 62%) and chemotherapy (14
ases, 48%).
Surgical margins were negative in nine patients, close in four,
ositive in ﬁve and unspeciﬁed in 11 cases.
Mean survival was 56.4 ± 64.3 months.
Two- and 5- year overall survivorship (OS) was 69% and 31%
espectively (Fig. 1).
The parameters showing a trend toward positive impact on
urvival were: male gender; non-smoker; positive alcohol con-
umption; age > 18 years; tumor size < 5 cm;  and location (nasal
yramid, jaw and maxillary sinus). Rhabdomyosarcoma and syn-
via sarcoma were the histological forms showing a trend toward
ositive impact on prognosis.
Age was the only variable that signiﬁcantly inﬂuenced survival
P = 0:022) (Fig. 2, Table 7).
Chemoradiotherapy was the treatment with the longest mean
urvival (71.5 months).
able 6
ean survival details (MS). Mean survival according to other parameters.
n MS
Smoking
With 4 44.8
Without 25 54.3
Alcohol
With 5 53.2
Without 24 52.6
Gender
Male 20 51.9
Female 9 31.4
Age
<  18 5 98.2
>  18 24 48.9
Tumor size
> 5 cm 9 27
<  5 cm 20 67.2
Metastases
With 5 22.2
Without 24 60.2
Recurrences
With 15 72.6
Without 14 34.5
Fig. 2. Kaplan–Meier age curve (P < 0.05).
Table 7
Mean survival details. Statistical signiﬁcance of the studied parameters.
Variable P
Age 0.022
Gender 0.638
Alcohol 0.478
Smoking 0.41
Recurrence 0.511
Tumor size 0.12
Metastases 0.108
Surgery 0.47
Histology 0.113
4. DiscussionSarcomas of the head and neck region are a heterogeneous group
of malignancies that display a wide spectrum of clinical behavior
[1].
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Most recent publications reported series of about 50 patients
r fewer, and are often not comparable. To date, the two  largest
ublished series included no more than 100 patients [2].
Comparison of survival outcomes between studies is challeng-
ng for several reasons:
inclusion and exclusion criteria according to sarcoma subtype
differ from one study to another;
a long study period is required to report meaningfully on a rare
disease such as head and neck sarcoma;
considerable changes in sarcoma classiﬁcation as well as in imag-
ing and primary and adjuvant treatment protocols may  have
occurred since the study period;
advances in immunohistochemistry together with changes in
nomenclature seem to have made accurate diagnosis of head and
neck sarcoma more reliable, but new studies incorporating these
developments are lacking [4].
The exclusion of 14 patients in the present study was a selection
ias implicit in the study design (incomplete information was  the
nly exclusion criterion).
The male/female ratio found in the literature was  1/1.1 [3]. The
resent series, in contrast, had a clear predominance of males.
Mean age was 45.9 years, which is consistent with the literature
3,7,8].
The most frequent clinical manifestations were similar to those
eported in the literature: neck mass (62%), epistaxis (14%) and
ysphonia (14%) [3].
Osteosarcoma is the most common sarcoma in the head and
eck region among adults, and rhabdomyosarcoma is the most
ommon in children [4].
These ﬁndings are conﬁrmed by the present study.
In the literature, head and neck sarcoma is associated with 5-
ear overall survivorship ranging from 32% to 87% [3,9–11]. The
resent study found 5-year survivorship of 31%, which is close to
he lower limit of the literature.
In some reviews, margin status, tumor grade and tumor size
ave been reported as prognostic factors, while in other studies no
rognostic factors could be identiﬁed [4].
In the present study, age was the only statistically signiﬁcant
ariable (P < 0.05), and therefore the only survival predictor.
Optimal treatment of most patients with sarcomas of the head
nd neck depends on a multidisciplinary approach with surgery,
hemotherapy and radiotherapy [1].
It is important that these patients be treated in a specialized unit
ith a multidisciplinary framework [2].
The management of head and neck sarcomas is primarily sur-
ical, followed by adjuvant radiotherapy for high-grade sarcomas,
arge tumors and close or positive margins [4].
In the present study, surgery was the most frequent treatment.
As in other head and neck cancers, primary combination treat-ents of radiotherapy and chemotherapy have obtained increasing
nterest [5].
In the present study, patients who were treated with radiothe-
apy and chemotherapy had longer survivals.
[ogy, Head and Neck diseases 131 (2014) 83–86
In the literature, approximately 10 to 30% of patients experience
remote metastases [12].
The present study found remote metastases in 17% of patients.
Moreover, some outcomes of the study are very difﬁcult to
explain, such as:
• lower average survival in patients with negative surgical margins;
• longer survival rates in patients with tumor recurrence;
• longer survival rates in patients with alcohol consumption.
These results may  be due to the fact that the study had
a small/heterogeneous sample, and to the different degrees of
aggressiveness of sarcomas.
5. Conclusion
All ﬁndings were limited by the fact that the sample was small
and heterogeneous.
This analysis showed a 5-year survival of 31%, which is close to
the lower limit the available data in the literature (32–87%) [4].
Age was  the only proven indicator of outcome.
New studies with larger samples are needed, in order to have
reliable data.
Therefore, to identify relevant information, it is essential to set
up prospective multicenter databases.
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